Arginine vasopressin prevents against Aβ25-35-induced impairment of spatial learning and memory in rats

Hormones and Behavior

Volumn 57, Issue 4-5, 2010, Pages 448-454

  Pan, Yan Fang ^a   Chen, Xiao Rong ^a   Wu, Mei Na ^a   Ma, Cun Gen ^b   Qi, Jin Shun ^a,b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b SHANXI DATONG UNIVERSITY   (China)

Author keywords

Amyloid protein (A ); Arginine vasopressin (AVP); Morris water maze; Spatial learning and memory

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ARGIPRESSIN;

ADULT ANIMAL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRAIN PROTECTION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING; VISION;

AMYLOID BETA-PROTEIN; ANIMALS; ARGININE VASOPRESSIN; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; LEARNING; MAZE LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RATS, WISTAR; SPACE PERCEPTION; SWIMMING;

EID: 77950953432     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2010.01.015     Document Type: Article

References (51)

1. Alkam T., Nitta A., Mizoguchi H., Itoh A., Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav. Brain Res. 2007, 180:139-145.
2. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 2002, 68:209-245.
3. Brinton R.E. Neuromodulation: associative and nonlinear adaptation. Brain Res. Bull. 1990, 24:651-658.
4. Brorson J.R., Bindokas V.P., Iwama T., Marcuccilli C.J., Chisholm J.C., Miller R.J. The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J. Neurobiol. 1995, 26:325-338.
5. Chen Q., Patel R., Sales A., Oji G., Kim J., Monreal A.W., Brinton R.D. Vasopressin-induced neurotrophism in cultured neurons of the cerebral cortex: dependency on calcium signaling and protein kinase C activity. Neuroscience 2000, 101:19-26.
6. Davis R.E., Doyle P.D., Carroll R.T., Emmerling M.R., Jaen J. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?. Arzneimittelforschung 1995, 45:425-431.
7. de Vries G.J., Miller M.A. Anatomy and function of extrahypothalamic vasopressin systems in the brain. Prog. Brain Res. 1998, 119:3-20.
8. Dietrich A., Allen J.D. Vasopressin and memory. I. The vasopressin analogue AVP4-9 enhances working memory as well as reference memory in the radial arm maze. Behav. Brain Res. 1997, 87:195-200.
9. Dietrich A., Allen J.D. Vasopressin and memory. II. Lesions to the hippocampus block the memory enhancing effects of AVP4-9 in the radial maze. Behav. Brain Res. 1997, 87:201-208.
10. Egashira N., Tanoue A., Higashihara F., Mishima K., Fukue Y., Takano Y., Tsujimoto G., Iwasaki K., Fujiwara M. V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci. Lett. 2004, 356:195-198.
11. Egashira N., Tanoue A., Tsujimoto G., Mishima K., Takano Y., Iwasaki K., Fujiwara M. Vasopressin receptor knockout mice as an animal model of psychiatric disorders. Nihon Shinkei Seishin Yakurigaku Zasshi. 2006, 26:101-105.
12. Engelmann M., Bures J., Landgraf R. Vasopressin administration via microdialysis into the septum interferes with the acquisition of spatial memory in rats. Neurosci. Lett. 1992, 142:69-72.
13. Engelmann M., Wotjak C.T., Neumann I., Ludwig M., Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: focus on learning and memory. Neurosci. Biobehav. Rev. 1996, 20:341-358.
14. Everts H.G., Koolhaas J.M. Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats. Behav. Brain Res. 1999, 99:7-16.
15. Fliers E., Swaab D.F. Activation of vasopressinergic and oxytocinergic neurons during aging in the Wistar rat. Peptides 1983, 4:165-170.
16. Fujiwara M., Ohgami Y., Inada K., Iwasaki K. Effect of active fragments of arginine-vasopressin on the disturbance of spatial cognition in rats. Behav. Brain Res. 1997, 83:91-96.
17. Fujiyoshi K., Suga H., Okamoto K., Nakamura S., Kameyama M. Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia. J. Neurol. Neurosurg. Psychiatry 1987, 50:929-932.
18. Gaffori O.J., De Wied D. Time-related memory effects of vasopressin analogues in rats. Pharmacol. Biochem. Behav. 1986, 25:1125-1129.
19. Good T.A., Murphy R.M. Effect of beta-amyloid block of the fast-inactivating K+ channel on intracellular Ca2+ and excitability in a modeled neuron. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:15130-15135.
20. Gouzenes L., Sabatier N., Richard P., Moos F.C., Dayanithi G. V1a- and V2-type vasopressin receptors mediate vasopressin-induced Ca2+ responses in isolated rat supraoptic neurones. J. Physiol. 1999, 517(Pt 3):771-779.
21. Hamburger-Bar R., Klein A., Belmaker R.H. The effect of chronic vs. acute injection of vasopressin on animal learning and memory. Peptides 1985, 6:23-25.
22. Hirate K., Hirano M., Nakajima Y., Hiyama A., Maeda O., Asakura W. No. 302, a newly synthesized [pGlu4, Cyt6]AVP(4-9) analogue, prevents the disruption of avoidance behavior. Behav. Brain Res. 1997, 83:205-208.
23. Hoogendijk J.E., Fliers E., Swaab D.F., Verwer R.W. Activation of vasopressin neurons in the human supraoptic and paraventricular nucleus in senescence and senile dementia. J. Neurol. Sci. 1985, 69:291-299.
24. Ishunina T.A., Swaab D.F. Neurohypophyseal peptides in aging and Alzheimer's disease. Ageing Res. Rev. 2002, 1:537-558.
25. Izquierdo L.A., Barros D.M., Medina J.H., Izquierdo I. Stress hormones enhance retrieval of fear conditioning acquired either one day or many months before. Behav. Pharmacol. 2002, 13:203-213.
26. Jing W., Guo F., Cheng L., Zhang J.F., Qi J.S. Arginine vasopressin prevents amyloid beta protein-induced impairment of long-term potentiation in rat hippocampus in vivo. Neurosci. Lett. 2009, 450:306-310.
27. Kovacs G.L., Veldhuis H.D., Versteeg D.H., De Wied D. Facilitation of avoidance behavior by vasopressin fragments microinjected into limbic-midbrain structures. Brain Res. 1986, 371:17-24.
28. Lippa C.F., Nee L.E., Mori H., St George-Hyslop P. Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 1998, 352:1117-1118.
29. Liu R.Y., Zhou J.N., Hoogendijk W.J., van Heerikhuize J., Kamphorst W., Unmehopa U.A., Hofman M.A., Swaab D.F. Decreased vasopressin gene expression in the biological clock of Alzheimer disease patients with and without depression. J. Neuropathol. Exp. Neurol. 2000, 59:314-322.
30. Mann D.M., Yates P.O., Marcyniuk B. Changes in Alzheimer's disease in the magnocellular neurons of the supraoptic and paraventricular nulei of the hypothalamus and their relationship to the noradrenergic deficit. Clin. Neuropathol. 1985, 4(3):127-134.
31. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
32. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996, 706:181-193.
33. Mazurek M.F., Beal M.F., Bird E.D., Martin J.B. Vasopressin in Alzheimer's disease: a study of postmortem brain concentrations. Ann. Neurol. 1986, 20:665-670.
34. Metzger D., Alescio-Lautier B., Bosler O., Devigne C., Soumireu-Mourat B. Effect of changes in the intrahippocampal vasopressin on memory retrieval and relearning. Behav. Neural. Biol. 1993, 59:29-48.
35. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res. 2002, 958:210-221.
36. Mihara T., Tarumi T., Sugimoto Y., Chen Z., Kamei C. [Arg8]-vasopressin-induced increase in intracellular Ca2+ concentration in cultured rat hippocampal neurons. Brain Res. Bull. 1999, 49:343-347.
37. Mishima K., Tsukikawa H., Inada K., Fujii M., Iwasaki K., Matsumoto Y., Abe K., Egawa T., Fujiwara M. Ameliorative effect of vasopressin-(4-9) through vasopressin V(1A) receptor on scopolamine-induced impairments of rat spatial memory in the eight-arm radial maze. Eur. J. Pharmacol. 2001, 427:43-52.
38. Mishima K., Tsukikawa H., Miura I., Inada K., Abe K., Matsumoto Y., Egashira N., Iwasaki K., Fujiwara M. Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. Neuropharmacology 2003, 44:541-552.
39. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of beta-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn. J. Pharmacol. 1997, 73:51-57.
40. Prediger R.D., Franco J.L., Pandolfo P., Medeiros R., Duarte F.S., Di Giunta G., Figueiredo C.P., Farina M., Calixto J.B., Takahashi R.N., Dafre A.L. Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: evidence for a dissociation between cognitive deficits and the glutathione system response. Behav. Brain Res. 2007, 177:205-213.
41. Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 2001, 105:845-852.
42. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
43. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Gulyaeva N.V. Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze. Neurosci. Behav. Physiol. 2005, 35:511-518.
44. Swaab D.F., Fliers E., Partiman T.S. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res. 1985, 342:37-44.
45. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakata A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension 2009, 54:782-787.
46. Ueda K., Shinohara S., Yagami T., Asakura K., Kawasaki K. Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: a possible involvement of free radicals. J. Neurochem. 1997, 68:265-271.
47. Van der Woude P.F., Goudsmit E., Wierda M., Purba J.S., Hofman M.A., Bogte H., Swaab D.F. No vasopressin cell loss in the human hypothalamus in aging and Alzheimer's disease. Neurobiol. Aging 1995, 16:11-18.
48. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:13217-13221.
49. Wang D., Noda Y., Zhou Y., Mouri A., Mizoguchi H., Nitta A., Chen W., Nabeshima T. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 2007, 32:1261-1271.
50. Zhang J.M., Wu M.N., Qi J.S., Qiao J.T. Amyloid beta-protein fragment 31-35 suppresses long-term potentiation in hippocampal CA1 region of rats in vivo. Synapse 2006, 60:307-313.
51. Zhou A.W., Li W.X., Guo J., Du Y.C. Facilitation of AVP(4-8) on gene expression of BDNF and NGF in rat brain. Peptides 1997, 18:1179-1187.